<?xml version="1.0" encoding="ASCII"?>
<biogps><data><item key="owner">ArrayExpress Uploader</item><item key="ownerprofile_id">arrayexpress_sid</item><item key="species">human</item><item key="factors"><item><item key="GSE7510GSM182021"/></item><item><item key="GSE7510GSM182022"/></item><item><item key="GSE7510GSM182023"/></item><item><item key="GSE7510GSM182024"/></item><item><item key="GSE7510GSM182025"/></item><item><item key="GSE7510GSM182026"/></item><item><item key="GSE7510GSM182027"/></item><item><item key="GSE7510GSM182028"/></item></item><item key="id">4912</item><item key="pop_total">0</item><item key="platform">4</item><item key="summary_wrapped">Allogeneic peripheral blood stem cell transplantation (PBSCT) is indicated for the treatment of high-risk hematological malignancies, and...</item><item key="geo_gse_id">E-GEOD-7510</item><item key="owner_profile">/profile/8773/arrayexpressuploader</item><item key="factor_count">0</item><item key="sample_count">8</item><item key="tags"><item>cancer</item><item>cell</item><item>dendritic</item><item>disease</item><item>genome</item><item>organ</item><item>peripheral</item><item>peripheral blood stem cell</item><item>stem cell</item></item><item key="lastmodified">Dec.12, 2014</item><item key="is_default">False</item><item key="geo_gds_id"/><item key="slug">transcription-profiling-of-human-leukocytes-from-p</item><item key="geo_id_plat">E-GEOD-7510_A-AFFY-44</item><item key="name">Transcription profiling of human leukocytes from peripheral blood stem cell transplant patients to investigate acute graft versus host disease aGVHD</item><item key="created">Sep.22, 2014</item><item key="summary">Allogeneic peripheral blood stem cell transplantation (PBSCT) is indicated for the treatment of high-risk hematological malignancies, and in some cases is a cancer cure. A major complication associated with PBSCT (affecting approximately half of recipients) is acute graft-versus-host disease (aGVHD). In aGVHD, alloreactive donor T cells becoming activated by host dendritic cells (DC) in response to pro-inflammatory cytokines released during the conditioning regimen. The result is donor-derived CD4+ T helper-type 1 (Th1) cells maturing and subsequently imposing cytolytic effector responses on host tissues, resulting in multi-organ damage. Despite this well-defined pathophysiological mechanism, there are no definitive markers for predicting aGVHD development or progression to clinically advanced stages. In the current study, we enrolled 8 PBSCT recipients in an IRB-approved study and collected peripheral blood at the time to engraftment. Of these, four patients developed aGVHD within 5-10 days post transplant. The remaining four patients were aGVHD-free.  Using total RNA collected from whole blood leukocytes, we analyzed each recipient&#8217;s gene expression profile on Affymetrix GeneChip Human Genome U133 Plus 2.0 microarrays. Experiment Overall Design: Samples 1-4 are control patients; 5-8 are aGVHD patients.  Peripheral blood was collected at engraftment and used for microarray analysis.  In analysing the data, the type of transplant (MUD, related) was used as a covariate to assess if there were significant changes in gene expression between the control (1-4) and aGVHD (5-8) groups, based on a 10% FDR with a pooled error estimate.</item><item key="source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-7510</item><item key="sample_source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-7510/samples/</item></data></biogps>
